Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy

Epigenetic Changes within the Promoter Regions of Antigen Processing Machinery Family Genes in Kazakh Primary Esophageal Squamous Cell Carcinoma

(2015) Ilyar Sheyhidin et al.   Asian Pacific Journal of Cancer Prevention

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma

(2015) Wei Dai et al.   Cancer Medicine

Three Tapasin Docking Sites in TAP Cooperate To Facilitate Transporter Stabilization and Heterodimerization

(2014) R. M. Leonhardt et al.   JOURNAL OF IMMUNOLOGY

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

(2013) Yun-Gyoo Lee et al.   BRITISH JOURNAL OF HAEMATOLOGY

MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells

(2013) P. Leone et al.   JNCI-Journal of the National Cancer Institute

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies

(2010) NAJET REBAÏ et al.   TISSUE ANTIGENS

Differential contribution of TAP and tapasin to HLA class I antigen expression

(2008) Alan Belicha-Villanueva et al.   IMMUNOLOGY

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

(2008) M Campoli et al.   ONCOGENE